{"success":true,"data":{"pressRelease":{"id":"167250","rtpr_id":"nACSH7XbGa-20261013","ticker":"HSPOF","exchange":"OTC","all_tickers":["HSPOF"],"title":"Horizon Space Acquisition I Corp. Announces Definitive Business Combination Agreement with ArcheNova Biotech Corp.","author":"ACCESSWIRE","published_at":"2026-10-13T11:00:01.155Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) /\nOctober 13, 2026 / Horizon Space Acquisition I Corp. (\"HSPO\") (OTCQB:HSPOF), a\npublicly traded special purpose acquisition company, and ArcheNova Biotech\nCorp. (\"ArcheNova\" or the \"Company\"), a clinical-stage, platform-based\nbiopharmaceutical company, focusing on the research, development, clinical\ntranslation, scalable manufacturing and global commercialization of innovative\ndrugs derived from mesenchymal stromal cell (MSC)-derived extracellular\nvesicles (EVs) and exosomes, today announced that they have entered into a\ndefinitive business combination agreement (the \"Business Combination\nAgreement\"). Upon completion of the business combination of HSPO and the\nCompany and related transactions pursuant to the Business Combination\nAgreement (collectively, the \"Proposed Transactions\"), ArcheNova Technology\nCo., Ltd, a Cayman Islands exempted company newly formed for purpose of\neffecting the Proposed Transactions (the \"Combined Company\" or \"PubCo\") will\nbe listed on The Nasdaq Stock Market LLC (\"Nasdaq\").\n\nThe closing of the Proposed Transactions is subject to customary closing\nconditions, including regulatory and shareholder approvals.\n\nArcheNova's MSC-Exosome Platform for Tissue Repair and Regenerative Medicine\n\nArcheNova has established a proprietary MSC-exosome therapeutics platform\nbuilt on an immortalized monoclonal MSC producer cell line, supported by a\ngood manufacturing practice (GMP) master cell bank, controlled manufacturing\nprocesses, and an integrated chemistry, manufacturing and controls (CMC)\nframework. This platform provides a renewable, defined biological source for\nscalable and reproducible exosome production, addressing key challenges of\ndonor variability and batch consistency.\n\nOne of ArcheNova's key advantages is the ability to develop multiple\ntherapeutic products from a common, process-defined exosome drug substance,\nleveraging shared manufacturing processes, analytical methods and quality\nsystems across indications. The same producer cell line underpins the\nArcheNova's foundational preclinical studies and clinical-stage development,\nproviding continuity from discovery to clinical translation.\n\nArcheNova's competitive protection extends beyond conventional patents.\nMSC-exosome products are complex biologics whose identity and activity depend\non their cell source and manufacturing process. Products derived from\ndifferent sources or processes cannot be presumed therapeutically equivalent,\ncreating potential barriers to biosimilar competition. Exclusive control of\nits producer cell line and proprietary manufacturing know-how may provide\ndurable competitive advantages beyond patent expiry.\n\nArcheNova is advancing therapeutic programs spanning dermatology, orthopedics,\nophthalmology, neurology and cardiology, at different stages of development.\nIts lead topical psoriasis program has completed a Phase I clinical trial in\nten healthy volunteers at Singapore's National University Hospital, and is\nbeing prepared for Phase II clinical evaluation.\n\nTogether, ArcheNova's scalable manufacturing platform, clinical progress and\ndurable competitive advantages provide a foundation for developing a\ndifferentiated portfolio of cell-free regenerative medicines.\n\nManagement Comments\n\nMingyu (\"Michael\") Li, Chief Executive Officer and Chairman of HSPO\n\n\"We are pleased to announce that HSPO has entered into the Business\nCombination Agreement with ArcheNova. ArcheNova's progress in developing\nexosome-based therapeutics for tissue repair and regenerative medicine aligns\nwith our objective of partnering with an innovative company positioned to\naddress significant unmet medical needs.\n\nWe look forward to working with the ArcheNova team and supporting its\ncontinued research, clinical development and growth. Together, we aim to\ncreate long-term value for shareholders and expand access to innovative\ntreatment options for patients worldwide.\"\n\nDr. LIM Sai Kiang, Chief Executive Officer, Chief Scientist and director of\nArcheNova\n\n\"We are thrilled to enter into the Business Combination Agreement and excited\nabout the contemplated Nasdaq listing, which will provide ArcheNova with a\nplatform to connect with growth capital and investors potentially across the\nglobe. Having access to the global capital market will empower our research\nand development as well as our novel pipeline products and fuel our growth and\nexpansion. We believe that empowered by the support from the public capital\nmarkets, we are well positioned to upgrade our R&D capabilities, advance our\npipeline development, enhance our innovation, and further grow our business.\"\n\nTransaction Overview\n\nUnder the terms of the Business Combination Agreement, ArcheNova International\nCo., Ltd, a Cayman Islands exempted company and a wholly-owned subsidiary of\nPubCo, will merge with and into HSPO, with HSPO as the surviving entity and a\nwholly-owned subsidiary of PubCo (the \"First Merger\"), and, following the\nFirst Merger, ArcheNova Global Co., Ltd, a Cayman Islands exempted company and\na wholly-owned subsidiary of PubCo, will merge with and into the Company, with\nthe Company as the surviving entity and a wholly-owned subsidiary of PubCo\n(the \"Second Merger\"). Upon consummation of the Proposed Transactions, HSPO's\nshareholders and the Company's shareholders will receive ordinary shares of\nPubCo (\"PubCo Ordinary Shares\") as consideration. HSPO warrants will be\nassumed by PubCo and converted into warrants to purchase PubCo Ordinary Shares\non substantially the same terms and conditions. PubCo Ordinary Shares are\nexpected to be listed and traded on Nasdaq following consummation of the\nProposed Transactions.\n\nThe Proposed Transactions have been unanimously approved by the boards of\ndirectors of both ArcheNova and HSPO. The Proposed Transactions are currently\nexpected to close in the first quarter of 2027, subject to regulatory and\nshareholder approvals, and other customary closing conditions. No assurances\ncan be made that the Proposed Transactions will be consummated on the terms or\ntime frame currently contemplated, or at all.\n\nUpon completion of the Proposed Transaction, PubCo will be led by Chief\nExecutive Officer and Chief Scientist, Dr. Lim Sai Kiang. Liu Ye will serve as\nthe Chief Financial Officer.\n\nAdditional information about the Proposed Transactions, including a copy of\nthe Business Combination Agreement, will be included in a Current Report on\nForm 8-K to be filed by HSPO with the Securities and Exchange Commission (the\n\"SEC\") and will be available at www.sec.gov.\n\nAdvisors\n\nCommerce & Finance Law Offices LLP is acting as legal counsel to ArcheNova.\nRobinson & Cole LLP is acting as legal counsel to HSPO.\n\nAbout ArcheNova Biotech Corp.\n\nArcheNova is a clinical-stage, platform-based biopharmaceutical company\nfocused on the research, development, clinical translation, scalable\nmanufacturing and global commercialization of innovative drugs derived from\nMSC-derived EVs and exosomes. ArcheNova's approach combines scientific\nexpertise with shared manufacturing processes and quality systems to translate\nadvances in MSC and exosome biology into new treatment options that address\nunmet medical needs and improve patients' health and quality of life.\nLeveraging a proprietary drug development and manufacturing platform, the\nCompany is advancing five product candidates across dermatology, orthopedics,\nophthalmology, neurology and cardiology. Its lead topical candidate for\npsoriasis has completed a Phase I study evaluating safety and tolerability in\nhealthy volunteers and is being prepared for a Phase II trial.\n\nAbout Horizon Space Acquisition I Corp.\n\nHorizon Space Acquisition I Corp. is a blank check company, also commonly\nreferred to as a special purpose acquisition company, or SPAC, formed for the\npurpose of effecting a merger, share exchange, asset acquisition, share\npurchase, recapitalization, reorganization or similar business combination\nwith one or more businesses or entities.\n\nAdditional Information and Where to Find It\n\nThis press release relates to a proposed business combination transaction\ninvolving HSPO and ArcheNova. In connection with the Proposed Transactions,\nHSPO, ArcheNova and PubCo intend to file with the SEC a registration statement\non Form F-4 that will include a proxy statement for shareholders of HSPO and\nthat will also constitute a prospectus with respect to the ordinary shares of\nPubCo to be issued in connection with the Proposed Transactions (the \"Proxy\nStatement/Prospectus\"). This document is not a substitute for the Proxy\nStatement/Prospectus. The definitive Proxy Statement/Prospectus (if and when\navailable) will be delivered to HSPO's shareholders. HSPO may also file other\nrelevant documents regarding the Proposed Transactions with the SEC. BEFORE\nMAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND SECURITY HOLDERS OF\nHSPO AND ARCHENOVA AND OTHER INTERESTED PARTIES ARE URGED TO READ THE\nREGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT\nDOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC IN CONNECTION WITH THE\nPROPOSED TRANSACTIONS, INCLUDING ANY AMENDMENTS OR SUPPLEMENTS TO THESE\nDOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE\nTHEY WILL CONTAIN IMPORTANT INFORMATION ABOUT HSPO, PUBCO, ARCHENOVA, THE\nPROPOSED TRANSACTIONS AND RELATED MATTERS.\n\nInvestors and security holders of HSPO and ArcheNova may obtain free copies of\nthe Proxy Statement/Prospectus (if and when available) and other documents\nthat are filed or will be filed with the SEC by HSPO, ArcheNova and PubCo\nthrough the website maintained by the SEC at www.sec.gov.\n\nParticipants in the Solicitation\n\nHSPO, ArcheNova and certain of their respective directors and executive\nofficers and other persons may be deemed to be participants in the\nsolicitation of proxies from the shareholders of HSPO in respect of the\nProposed Transactions. Information regarding HSPO's directors and executive\nofficers is available in HSPO's filings with the SEC. Additional information\nregarding the persons who may, under the rules of the SEC, be deemed to be\nparticipants in the proxy solicitation relating to the Transactions and a\ndescription of their direct and indirect interests, by security holdings or\notherwise, will be contained in the Proxy Statement/Prospectus when it becomes\navailable.\n\nNo Offer or Solicitation\nThis press release is for informational purposes only and is not intended to\nand shall not constitute an offer to sell or the solicitation of an offer to\nsell or to buy any securities or a solicitation of any proxy, consent, vote or\napproval with respect to any securities in respect of the Proposed\nTransactions and is not a substitute for the Proxy Statement/Prospectus or any\nother document that HSPO or PubCo may file with the SEC or send to HSPO's or\nArcheNova's shareholders in connection with the Proposed Transactions. No\noffer, sale, issuance or transfer of securities shall be made in any\njurisdiction in which such offer, sale, issuance or transfer would be unlawful\nprior to registration or qualification under the securities laws of any such\njurisdiction.\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains \"forward-looking statements\" that involve risks\nand uncertainties. Forward-looking statements are statements that are not\nhistorical facts and may be accompanied by words that convey projected future\nevents or outcomes, such as \"believe,\" \"may,\" \"will,\" \"estimate,\" \"continue,\"\n\"anticipate,\" \"design,\" \"intend,\" \"expect,\" \"could,\" \"plan,\" \"potential,\"\n\"predict,\" \"seek,\" \"target,\" \"aim,\" \"plan,\" \"project,\" \"forecast,\" \"should,\"\n\"would,\" or variations of such words or by expressions of similar meaning.\nSuch forward-looking statements, including, without limitation, statements\nregarding anticipated financial and operational results, projections of market\nopportunity and expectations, the estimated post-transaction enterprise value,\nthe advantages and expected growth of PubCo, the cash position of PubCo\nfollowing the consummation of the Proposed Transactions, the ability of HSPO\nand the Company to consummate the Proposed Transactions and the timing of such\nconsummation, are subject to risks and uncertainties, which could cause actual\nresults to differ from the forward-looking statements. These risks and\nuncertainties include, but are not limited to, those risk factors described in\nthe section entitled \"Risk Factors\" in HSPO's Annual Report on Form 10-K for\nthe year ended December 31, 2025 filed with the SEC on April 15, 2026 (the\n\"Form 10-K\"), and in other documents filed by HSPO with the SEC from time to\ntime. Important factors that could cause PubCo's actual results or outcomes to\ndiffer materially from those discussed in the forward-looking statements\ninclude: (i) HSPO's or the Company's limited operating history; (ii)general\neconomic and market conditions impacting demand for the products and services\nof the Company; (iii) the inability to complete the Proposed Transactions;\n(iv) the inability to recognize the anticipated benefits of the Proposed\nTransactions, which may be affected by, among other things, the amount of cash\navailable following any redemptions by HSPO's shareholders; and (v) the\nability of PubCo to obtain or maintain the listing of its securities on Nasdaq\nfollowing the consummation of the Proposed Transactions; costs related to the\nProposed Transactions; and such other risks and uncertainties as are discussed\nin the Form 10-K and the proxy statement/prospectus to be filed with the SEC\nrelating to the Proposed Transactions. Other factors include the possibility\nthat the Proposed Transactions do not close, including due to the failure to\nreceive required security holder approvals or the failure to satisfy other\nclosing conditions under the Business Combination Agreement.\n\nHSPO, the Company, and PubCo each expressly disclaims any obligations or\nundertaking to release publicly any updates or revisions to any\nforward-looking statements contained herein to reflect any change in the\nexpectations of HSPO, the Company or PubCo with respect thereto or any change\nin events, conditions or circumstances on which any statement is based, except\nas required by law.\n\nContact Information:\n\nHorizon Space Acquisition I Corp. Contact:\nMingyu (Michael) Li\nChief Executive Officer\nTel: (646) 257-5537\nEmail: mcli@horizonspace.cc\n\nArcheNova Biotech Corp. Contact:\nLIU Ye\nChief Financial Officer\nTel: +65 91901568\nEmail: liu.ye@paracrinetherapeutics.com\n\nSOURCE: Horizon Space Acquisition I Corp.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/banking-and-financial-services/horizon-space-acquisition-i-corp.-announces-definitive-business-comb-1235647)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSH7XbGa-20261013","title":"Horizon Space Acquisition I Corp. Announces Definitive Business Combination Agreement with ArcheNova Biotech Corp.","author":"ACCESSWIRE","ticker":"HSPOF","created":"2026-10-13T11:00:01.155Z","tickers":["HSPOF"],"exchange":"OTC","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) /\nOctober 13, 2026 / Horizon Space Acquisition I Corp. (\"HSPO\") (OTCQB:HSPOF), a\npublicly traded special purpose acquisition company, and ArcheNova Biotech\nCorp. (\"ArcheNova\" or the \"Company\"), a clinical-stage, platform-based\nbiopharmaceutical company, focusing on the research, development, clinical\ntranslation, scalable manufacturing and global commercialization of innovative\ndrugs derived from mesenchymal stromal cell (MSC)-derived extracellular\nvesicles (EVs) and exosomes, today announced that they have entered into a\ndefinitive business combination agreement (the \"Business Combination\nAgreement\"). Upon completion of the business combination of HSPO and the\nCompany and related transactions pursuant to the Business Combination\nAgreement (collectively, the \"Proposed Transactions\"), ArcheNova Technology\nCo., Ltd, a Cayman Islands exempted company newly formed for purpose of\neffecting the Proposed Transactions (the \"Combined Company\" or \"PubCo\") will\nbe listed on The Nasdaq Stock Market LLC (\"Nasdaq\").\n\nThe closing of the Proposed Transactions is subject to customary closing\nconditions, including regulatory and shareholder approvals.\n\nArcheNova's MSC-Exosome Platform for Tissue Repair and Regenerative Medicine\n\nArcheNova has established a proprietary MSC-exosome therapeutics platform\nbuilt on an immortalized monoclonal MSC producer cell line, supported by a\ngood manufacturing practice (GMP) master cell bank, controlled manufacturing\nprocesses, and an integrated chemistry, manufacturing and controls (CMC)\nframework. This platform provides a renewable, defined biological source for\nscalable and reproducible exosome production, addressing key challenges of\ndonor variability and batch consistency.\n\nOne of ArcheNova's key advantages is the ability to develop multiple\ntherapeutic products from a common, process-defined exosome drug substance,\nleveraging shared manufacturing processes, analytical methods and quality\nsystems across indications. The same producer cell line underpins the\nArcheNova's foundational preclinical studies and clinical-stage development,\nproviding continuity from discovery to clinical translation.\n\nArcheNova's competitive protection extends beyond conventional patents.\nMSC-exosome products are complex biologics whose identity and activity depend\non their cell source and manufacturing process. Products derived from\ndifferent sources or processes cannot be presumed therapeutically equivalent,\ncreating potential barriers to biosimilar competition. Exclusive control of\nits producer cell line and proprietary manufacturing know-how may provide\ndurable competitive advantages beyond patent expiry.\n\nArcheNova is advancing therapeutic programs spanning dermatology, orthopedics,\nophthalmology, neurology and cardiology, at different stages of development.\nIts lead topical psoriasis program has completed a Phase I clinical trial in\nten healthy volunteers at Singapore's National University Hospital, and is\nbeing prepared for Phase II clinical evaluation.\n\nTogether, ArcheNova's scalable manufacturing platform, clinical progress and\ndurable competitive advantages provide a foundation for developing a\ndifferentiated portfolio of cell-free regenerative medicines.\n\nManagement Comments\n\nMingyu (\"Michael\") Li, Chief Executive Officer and Chairman of HSPO\n\n\"We are pleased to announce that HSPO has entered into the Business\nCombination Agreement with ArcheNova. ArcheNova's progress in developing\nexosome-based therapeutics for tissue repair and regenerative medicine aligns\nwith our objective of partnering with an innovative company positioned to\naddress significant unmet medical needs.\n\nWe look forward to working with the ArcheNova team and supporting its\ncontinued research, clinical development and growth. Together, we aim to\ncreate long-term value for shareholders and expand access to innovative\ntreatment options for patients worldwide.\"\n\nDr. LIM Sai Kiang, Chief Executive Officer, Chief Scientist and director of\nArcheNova\n\n\"We are thrilled to enter into the Business Combination Agreement and excited\nabout the contemplated Nasdaq listing, which will provide ArcheNova with a\nplatform to connect with growth capital and investors potentially across the\nglobe. Having access to the global capital market will empower our research\nand development as well as our novel pipeline products and fuel our growth and\nexpansion. We believe that empowered by the support from the public capital\nmarkets, we are well positioned to upgrade our R&D capabilities, advance our\npipeline development, enhance our innovation, and further grow our business.\"\n\nTransaction Overview\n\nUnder the terms of the Business Combination Agreement, ArcheNova International\nCo., Ltd, a Cayman Islands exempted company and a wholly-owned subsidiary of\nPubCo, will merge with and into HSPO, with HSPO as the surviving entity and a\nwholly-owned subsidiary of PubCo (the \"First Merger\"), and, following the\nFirst Merger, ArcheNova Global Co., Ltd, a Cayman Islands exempted company and\na wholly-owned subsidiary of PubCo, will merge with and into the Company, with\nthe Company as the surviving entity and a wholly-owned subsidiary of PubCo\n(the \"Second Merger\"). Upon consummation of the Proposed Transactions, HSPO's\nshareholders and the Company's shareholders will receive ordinary shares of\nPubCo (\"PubCo Ordinary Shares\") as consideration. HSPO warrants will be\nassumed by PubCo and converted into warrants to purchase PubCo Ordinary Shares\non substantially the same terms and conditions. PubCo Ordinary Shares are\nexpected to be listed and traded on Nasdaq following consummation of the\nProposed Transactions.\n\nThe Proposed Transactions have been unanimously approved by the boards of\ndirectors of both ArcheNova and HSPO. The Proposed Transactions are currently\nexpected to close in the first quarter of 2027, subject to regulatory and\nshareholder approvals, and other customary closing conditions. No assurances\ncan be made that the Proposed Transactions will be consummated on the terms or\ntime frame currently contemplated, or at all.\n\nUpon completion of the Proposed Transaction, PubCo will be led by Chief\nExecutive Officer and Chief Scientist, Dr. Lim Sai Kiang. Liu Ye will serve as\nthe Chief Financial Officer.\n\nAdditional information about the Proposed Transactions, including a copy of\nthe Business Combination Agreement, will be included in a Current Report on\nForm 8-K to be filed by HSPO with the Securities and Exchange Commission (the\n\"SEC\") and will be available at www.sec.gov.\n\nAdvisors\n\nCommerce & Finance Law Offices LLP is acting as legal counsel to ArcheNova.\nRobinson & Cole LLP is acting as legal counsel to HSPO.\n\nAbout ArcheNova Biotech Corp.\n\nArcheNova is a clinical-stage, platform-based biopharmaceutical company\nfocused on the research, development, clinical translation, scalable\nmanufacturing and global commercialization of innovative drugs derived from\nMSC-derived EVs and exosomes. ArcheNova's approach combines scientific\nexpertise with shared manufacturing processes and quality systems to translate\nadvances in MSC and exosome biology into new treatment options that address\nunmet medical needs and improve patients' health and quality of life.\nLeveraging a proprietary drug development and manufacturing platform, the\nCompany is advancing five product candidates across dermatology, orthopedics,\nophthalmology, neurology and cardiology. Its lead topical candidate for\npsoriasis has completed a Phase I study evaluating safety and tolerability in\nhealthy volunteers and is being prepared for a Phase II trial.\n\nAbout Horizon Space Acquisition I Corp.\n\nHorizon Space Acquisition I Corp. is a blank check company, also commonly\nreferred to as a special purpose acquisition company, or SPAC, formed for the\npurpose of effecting a merger, share exchange, asset acquisition, share\npurchase, recapitalization, reorganization or similar business combination\nwith one or more businesses or entities.\n\nAdditional Information and Where to Find It\n\nThis press release relates to a proposed business combination transaction\ninvolving HSPO and ArcheNova. In connection with the Proposed Transactions,\nHSPO, ArcheNova and PubCo intend to file with the SEC a registration statement\non Form F-4 that will include a proxy statement for shareholders of HSPO and\nthat will also constitute a prospectus with respect to the ordinary shares of\nPubCo to be issued in connection with the Proposed Transactions (the \"Proxy\nStatement/Prospectus\"). This document is not a substitute for the Proxy\nStatement/Prospectus. The definitive Proxy Statement/Prospectus (if and when\navailable) will be delivered to HSPO's shareholders. HSPO may also file other\nrelevant documents regarding the Proposed Transactions with the SEC. BEFORE\nMAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND SECURITY HOLDERS OF\nHSPO AND ARCHENOVA AND OTHER INTERESTED PARTIES ARE URGED TO READ THE\nREGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT\nDOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC IN CONNECTION WITH THE\nPROPOSED TRANSACTIONS, INCLUDING ANY AMENDMENTS OR SUPPLEMENTS TO THESE\nDOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE\nTHEY WILL CONTAIN IMPORTANT INFORMATION ABOUT HSPO, PUBCO, ARCHENOVA, THE\nPROPOSED TRANSACTIONS AND RELATED MATTERS.\n\nInvestors and security holders of HSPO and ArcheNova may obtain free copies of\nthe Proxy Statement/Prospectus (if and when available) and other documents\nthat are filed or will be filed with the SEC by HSPO, ArcheNova and PubCo\nthrough the website maintained by the SEC at www.sec.gov.\n\nParticipants in the Solicitation\n\nHSPO, ArcheNova and certain of their respective directors and executive\nofficers and other persons may be deemed to be participants in the\nsolicitation of proxies from the shareholders of HSPO in respect of the\nProposed Transactions. Information regarding HSPO's directors and executive\nofficers is available in HSPO's filings with the SEC. Additional information\nregarding the persons who may, under the rules of the SEC, be deemed to be\nparticipants in the proxy solicitation relating to the Transactions and a\ndescription of their direct and indirect interests, by security holdings or\notherwise, will be contained in the Proxy Statement/Prospectus when it becomes\navailable.\n\nNo Offer or Solicitation\nThis press release is for informational purposes only and is not intended to\nand shall not constitute an offer to sell or the solicitation of an offer to\nsell or to buy any securities or a solicitation of any proxy, consent, vote or\napproval with respect to any securities in respect of the Proposed\nTransactions and is not a substitute for the Proxy Statement/Prospectus or any\nother document that HSPO or PubCo may file with the SEC or send to HSPO's or\nArcheNova's shareholders in connection with the Proposed Transactions. No\noffer, sale, issuance or transfer of securities shall be made in any\njurisdiction in which such offer, sale, issuance or transfer would be unlawful\nprior to registration or qualification under the securities laws of any such\njurisdiction.\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains \"forward-looking statements\" that involve risks\nand uncertainties. Forward-looking statements are statements that are not\nhistorical facts and may be accompanied by words that convey projected future\nevents or outcomes, such as \"believe,\" \"may,\" \"will,\" \"estimate,\" \"continue,\"\n\"anticipate,\" \"design,\" \"intend,\" \"expect,\" \"could,\" \"plan,\" \"potential,\"\n\"predict,\" \"seek,\" \"target,\" \"aim,\" \"plan,\" \"project,\" \"forecast,\" \"should,\"\n\"would,\" or variations of such words or by expressions of similar meaning.\nSuch forward-looking statements, including, without limitation, statements\nregarding anticipated financial and operational results, projections of market\nopportunity and expectations, the estimated post-transaction enterprise value,\nthe advantages and expected growth of PubCo, the cash position of PubCo\nfollowing the consummation of the Proposed Transactions, the ability of HSPO\nand the Company to consummate the Proposed Transactions and the timing of such\nconsummation, are subject to risks and uncertainties, which could cause actual\nresults to differ from the forward-looking statements. These risks and\nuncertainties include, but are not limited to, those risk factors described in\nthe section entitled \"Risk Factors\" in HSPO's Annual Report on Form 10-K for\nthe year ended December 31, 2025 filed with the SEC on April 15, 2026 (the\n\"Form 10-K\"), and in other documents filed by HSPO with the SEC from time to\ntime. Important factors that could cause PubCo's actual results or outcomes to\ndiffer materially from those discussed in the forward-looking statements\ninclude: (i) HSPO's or the Company's limited operating history; (ii)general\neconomic and market conditions impacting demand for the products and services\nof the Company; (iii) the inability to complete the Proposed Transactions;\n(iv) the inability to recognize the anticipated benefits of the Proposed\nTransactions, which may be affected by, among other things, the amount of cash\navailable following any redemptions by HSPO's shareholders; and (v) the\nability of PubCo to obtain or maintain the listing of its securities on Nasdaq\nfollowing the consummation of the Proposed Transactions; costs related to the\nProposed Transactions; and such other risks and uncertainties as are discussed\nin the Form 10-K and the proxy statement/prospectus to be filed with the SEC\nrelating to the Proposed Transactions. Other factors include the possibility\nthat the Proposed Transactions do not close, including due to the failure to\nreceive required security holder approvals or the failure to satisfy other\nclosing conditions under the Business Combination Agreement.\n\nHSPO, the Company, and PubCo each expressly disclaims any obligations or\nundertaking to release publicly any updates or revisions to any\nforward-looking statements contained herein to reflect any change in the\nexpectations of HSPO, the Company or PubCo with respect thereto or any change\nin events, conditions or circumstances on which any statement is based, except\nas required by law.\n\nContact Information:\n\nHorizon Space Acquisition I Corp. Contact:\nMingyu (Michael) Li\nChief Executive Officer\nTel: (646) 257-5537\nEmail: mcli@horizonspace.cc\n\nArcheNova Biotech Corp. Contact:\nLIU Ye\nChief Financial Officer\nTel: +65 91901568\nEmail: liu.ye@paracrinetherapeutics.com\n\nSOURCE: Horizon Space Acquisition I Corp.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/banking-and-financial-services/horizon-space-acquisition-i-corp.-announces-definitive-business-comb-1235647)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-10-13T11:00:01.468122415Z","server_sent_at_ms":1791889201468},"received_at":"2026-10-13T11:00:01.520Z","source_url":"https://www.accessnewswire.com/newsroom/en/banking-and-financial-services/horizon-space-acquisition-i-corp.-announces-definitive-business-comb-1235647"},"analysis":{"id":"155566","press_release_id":"167250","analysis_json":{"industry":null,"redFlags":["No deal value, enterprise value or trust cash figures disclosed","Closing subject to regulatory and shareholder approvals; completion not assured","Deal contingent on post-redemption cash available to the SPAC","Filer is a SPAC trading on OTCQB; Nasdaq listing of combined entity not yet assured"],"eventType":"m_and_a","narrative":"Horizon Space Acquisition I Corp. signed a definitive business combination agreement with ArcheNova Biotech Corp., a clinical-stage exosome-based biopharmaceutical company, with the combined company expected to list on Nasdaq.\n\nArcheNova is advancing five product candidates across dermatology, orthopedics, ophthalmology, neurology and cardiology; its lead topical psoriasis program completed a Phase I trial in ten healthy volunteers at Singapore's National University Hospital and is preparing for Phase II.\n\nClosing is expected in Q1 2027, subject to regulatory and shareholder approvals, with Dr. Lim Sai Kiang as CEO and Liu Ye as CFO of the combined company. No deal value or financial terms were disclosed.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"SPAC HSPOF finds its target in clinical-stage exosome biotech ArcheNova with a planned Nasdaq uplisting -- watch F-4 and redemption levels."},"keyFigures":{"drugName":"topical psoriasis candidate (MSC-derived exosome)","phaseOfTrial":"Phase I completed; preparing Phase II","customDimensions":{"expected_close":"Q1 2027","combined_listing":"Nasdaq","pipeline_candidates":5}},"quotedText":"ArcheNova's progress in developing exosome-based therapeutics for tissue repair and regenerative medicine aligns with our objective of partnering with an innovative company positioned to address significant unmet medical needs.","namedEntities":{"people":[{"name":"Mingyu (Michael) Li","role":"CEO and Chairman of HSPO"},{"name":"Dr. Lim Sai Kiang","role":"CEO, Chief Scientist and director of ArcheNova; future CEO of PubCo"},{"name":"Liu Ye","role":"future CFO of PubCo; ArcheNova CFO"}],"products":["MSC-exosome therapeutics platform","topical psoriasis program"],"companies":[{"name":"Horizon Space Acquisition I Corp.","ticker":"HSPOF","relationship":"SPAC acquirer"},{"name":"ArcheNova Biotech Corp.","relationship":"target"},{"name":"Commerce & Finance Law Offices LLP","relationship":"legal counsel to ArcheNova"},{"name":"Robinson & Cole LLP","relationship":"legal counsel to HSPO"},{"name":"National University Hospital (Singapore)","relationship":"clinical trial site"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"Definitive business combination agreement between the SPAC filer (HSPO) and clinical-stage biotech ArcheNova, with a Nasdaq uplisting planned. M&A events score 4-5; no deal value or financial terms were disclosed, so 4."},"tickerRelevance":{"others":[],"primary":"HSPOF"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap SPAC on OTCQB","eventGravity":"definitive SPAC merger agreement","sectorWeight":"biotech target","financialTermsDisclosed":false}},"event_type":"m_and_a","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"Horizon Space Acquisition I Corp. signed a definitive business combination agreement with ArcheNova Biotech Corp., a clinical-stage exosome-based biopharmaceutical company, with the combined company expected to list on Nasdaq.\n\nArcheNova is advancing five product candidates across dermatology, orthopedics, ophthalmology, neurology and cardiology; its lead topical psoriasis program completed a Phase I trial in ten healthy volunteers at Singapore's National University Hospital and is preparing for Phase II.\n\nClosing is expected in Q1 2027, subject to regulatory and shareholder approvals, with Dr. Lim Sai Kiang as CEO and Liu Ye as CFO of the combined company. No deal value or financial terms were disclosed.","key_figures":{"drugName":"topical psoriasis candidate (MSC-derived exosome)","phaseOfTrial":"Phase I completed; preparing Phase II","customDimensions":{"expected_close":"Q1 2027","combined_listing":"Nasdaq","pipeline_candidates":5}},"named_entities":{"people":[{"name":"Mingyu (Michael) Li","role":"CEO and Chairman of HSPO"},{"name":"Dr. Lim Sai Kiang","role":"CEO, Chief Scientist and director of ArcheNova; future CEO of PubCo"},{"name":"Liu Ye","role":"future CFO of PubCo; ArcheNova CFO"}],"products":["MSC-exosome therapeutics platform","topical psoriasis program"],"companies":[{"name":"Horizon Space Acquisition I Corp.","ticker":"HSPOF","relationship":"SPAC acquirer"},{"name":"ArcheNova Biotech Corp.","relationship":"target"},{"name":"Commerce & Finance Law Offices LLP","relationship":"legal counsel to ArcheNova"},{"name":"Robinson & Cole LLP","relationship":"legal counsel to HSPO"},{"name":"National University Hospital (Singapore)","relationship":"clinical trial site"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T11:00:18.298Z","global_importance":35,"audience_relevance":25,"importance_components":{"tickerTier":"micro-cap SPAC on OTCQB","eventGravity":"definitive SPAC merger agreement","sectorWeight":"biotech target","financialTermsDisclosed":false}},"durationMs":6952,"modelName":"glm-5.3-flashx"}}